` PROC (Procaps Group SA) vs S&P 500 Comparison - Alpha Spread

PROC
vs
S&P 500

Over the past 12 months, PROC has underperformed S&P 500, delivering a return of -58% compared to the S&P 500's +14% growth.

Stocks Performance
PROC vs S&P 500

Loading
PROC
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PROC vs S&P 500

Performance Gap Between PROC and GSPC
HIDDEN
Show

Performance By Year
PROC vs S&P 500

Loading
PROC
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Procaps Group SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Procaps Group SA
Glance View

Market Cap
124.1m USD
Industry
Pharmaceuticals

Procaps Group SA develops pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.

PROC Intrinsic Value
Not Available
Back to Top